There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Unity Biotechnology (UBX – Research Report) and Axcella Health (AXLA – Research Report) with bullish sentiments.
Unity Biotechnology (UBX)
Wedbush analyst Andreas Argyrides maintained a Buy rating on Unity Biotechnology today and set a price target of $36.00. The company’s shares closed last Tuesday at $2.75, close to its 52-week low of $2.46.
According to TipRanks.com, Argyrides is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $34.00 average price target, an 836.6% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Axcella Health (AXLA)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Axcella Health, with a price target of $6.00. The company’s shares closed last Tuesday at $1.11, close to its 52-week low of $1.05.
According to TipRanks.com, Moussatos has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axcella Health with a $7.20 average price target, representing a 490.2% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on UBX:
- Sotera Health Announces Alex Dimitrief as General Counsel
- Stock Market Today: Futures Up Ahead of Another Interest Rate Hike
- Zeta Global Holdings Corp (ZETA) Receives a Buy from Needham
- Siebert Williams Shank & Co Keeps Their Buy Rating on Magnolia Oil & Gas (MGY)
- Siebert Williams Shank & Co Keeps Their Buy Rating on Chesapeake Energy (CHK)
